Patented small molecule inhibitors in the ubiquitin proteasome system.
Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade(R) (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma establishes this system as a valid target for cancer treatment. We review here new patented proteasome inhibitors and patented small molecule inhibitors targeting more specific UPS components, such as E3 ubiquitin ligases and deubiquitylating enzymes. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).
Hybrigenics SA, 3-5 Impasse Reille, 75014 Paris, France. pguedat@hybrigenics.com
Philippe
P
Guédat
Frédéric
F
Colland
D000818:Animals; D006801:Humans; D004366:Nonprescription Drugs / Q000737:chemistry / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D043743:Ubiquitin-Protein Ligase Complexes / Q000037:antagonists & inhibitors* / Q000378:metabolism
D004366:Nonprescription Drugs; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D043743:Ubiquitin-Protein Ligase Complexes; D046988:Proteasome Endopeptidase Complex